A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

Phase 1

Completed

• Conditions: Alzheimer's Disease; Huntington's Disease
• Interventions: Drug: Dimebon

• Registration Number: NCT00824590
• Lead Sponsor: Pfizer

Brief Summary

This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon. This study is also to assess the safety and tolerability of a single oral 20-mg dose of Dimebon in subjects with severe renal impairment and subjects with normal renal function.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-01-12
• Study First Submitted QC: 2009-01-16
• Study First Posted: 2009-01-19
• Study Start: 2009-02
• Primary Completion: 2009-10
• Study Completion: 2009-10
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-29
• Last Update Posted: 2009-12-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Male and/or female subjects between the ages of 18 and 75 years, inclusive
• For severe renal impairment group, subjects with creatinine clearance of less than 30 mL/min, but not yet on dialysis and in good general health commensurate with the population with chronic renal disease; however, subjects with type 1 and 2 diabetes that are reasonably controlled and who do not have a predisposition to severe hypoglycemia can both be included.
• For normal renal function group, healthy subjects with creatinine clearance of greater than 80mL/min and demographically comparable to subjects with impaired renal function

Exclusion Criteria

• Pregnant or nursing women; women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception as outlined in the protocol from at least 14 days prior to the first dose of study medication.
• For normal renal function group, use of prescription or non-prescription drugs, vitamins, or dietary supplements within 7 days of 5 half-lives (whichever is longer) prior to the first dose of study medication.

Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication. Acetaminophen at doses of ≤ 2 grams/day is permitted.

• For renal impairment group, a known history of clinically significant coronary heart disease, cerebrovascular disease or peripheral vascular disease and/or an event/intervention during the past 6 months. Systemic therapy with CYP3A or CYP2D6 inhibitors within 7 days or 5 halflives (whichever is longer) prior to the first dose of trial medication.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Severe renal impairment group	Dimebon	Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
normal renal function	Dimebon	Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function

Primary Outcome Measures

Name	Time	Method
Plasma drug concentrations	96

Secondary Outcome Measures

Name	Time	Method
Safety assessment including physical/neurological examination findings, clinical safety laboratory assessments, 12-lead ECGs, vital sign measurements, and adverse event monitoring.	96

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 St. Paul, Minnesota, United States